Companies › DNTH

DIANTHUS THERAPEUTICS INC (DNTH)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001690585 · EDGAR filings · Updated 2026-07-28

DIANTHUS THERAPEUTICS INC (DNTH) has reported institutional ownership of 139.7%, with 241 institutional managers holding positions valued at $5.17B per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings.

Filings this week (1)

• 2026-07-28 — SCHEDULE 13G/A filed

Every filing links to the official SEC document. Real-time filing alerts for this company are available inside the app.

Latest updates

• 2026-07-13 — Insider transaction reported (Form 4)
• 2026-07-09 — Notice of proposed sale filed (Form 144)
• 2026-06-18 — Insider transaction reported (Form 4)
• 2026-06-17 — Notice of proposed sale filed (Form 144)
• 2026-06-12 — Current report (8-K) filed

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, DIANTHUS THERAPEUTICS INC has 241 institutional holders and institutional ownership of 139.7%.

Insider activity

Insiders reported 36 transactions (0 buys, 18 sells) across 5 reporting insiders, with a net reported value of −$27.5M.

Data flags from SEC filings

Related companies

BIO RAD LABS INC (BIO) · LANTHEUS HLDGS INC (LNTH) · AVANTOR INC (AVTR) · QIAGEN NV (QGEN) · CHEMED CORP NEW (CHE) · BRUKER CORP COM (BRKR)